Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ovid Therapeutics Inc (OVID)
NASDAQ:OVID
Ovid Therapeutics (OVID) Stock Price & Analysis
1,254 Followers
OVID Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.68 - $4.14
Previous Close$0.86
Volume834.04K
Average Volume (3M)825.99K
Market Cap
$61.17M
Enterprise Value-$13.39M
Total Cash (Recent Filing)$90.26M
Total Debt (Recent Filing)$15.70M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Aug 07, 2024EPS Estimate
-$0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding70,944,627
10 Day Avg. Volume3,130,218
30 Day Avg. Volume825,991
Standard Deviation0.24
R-Squared0.02
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)0.71
Price to Sales (P/S)141.28
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-28.28
Enterprise Value/Gross Profit-34.19
Enterprise Value/Ebitda0.27
Forecast
1Y Price Target
$3.70Price Target Upside378.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Ovid Therapeutics News
PremiumCompany Announcements
Ovid Therapeutics Announces Workforce Reduction to Extend Runway
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsA pooled analysis of DS patients from the P3 SKYLINE and P2 ELEKTRA studies showed Soticlestat significantly reduced convulsive seizure frequency from baseline compared to placebo.
Drug ApprovalOV888 met the primary endpoint, demonstrating favorable safety and tolerability.
Pipeline DevelopmentOvid announced a collaboration with Sam Waksal’s Graviton following the sale of Kadmon and its ROCK2 inhibitor to Sanofi.
Bears Say
Clinical Trial FailuresSoticlestat did not demonstrate a statistically significant reduction from baseline in convulsive seizures versus placebo.
Financial PerformanceOVID reported 1Q24 licensing revenues of $148K and net loss of $11.7MM.
Workforce ReductionManagement cut headcount by 17 employees, which is 43% of its workforce.
---
Ownership Overview
16.94% Insiders
8.99% Mutual Funds
44.68% Other Institutional Investors
29.39% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OVID FAQ
What was Ovid Therapeutics Inc’s price range in the past 12 months?
Ovid Therapeutics Inc lowest stock price was $0.68 and its highest was $4.14 in the past 12 months.
What is Ovid Therapeutics Inc’s market cap?
Currently, no data Available
When is Ovid Therapeutics Inc’s upcoming earnings report date?
Ovid Therapeutics Inc’s upcoming earnings report date is Aug 07, 2024 which is in 35 days.
How were Ovid Therapeutics Inc’s earnings last quarter?
Ovid Therapeutics Inc released its earnings results on May 14, 2024. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.223 by $0.053.
Is Ovid Therapeutics Inc overvalued?
According to Wall Street analysts Ovid Therapeutics Inc’s price is currently Undervalued.
Does Ovid Therapeutics Inc pay dividends?
Ovid Therapeutics Inc does not currently pay dividends.
What is Ovid Therapeutics Inc’s EPS estimate?
Ovid Therapeutics Inc’s EPS estimate is -$0.22.
How many shares outstanding does Ovid Therapeutics Inc have?
Ovid Therapeutics Inc has 70,944,626 shares outstanding.
What happened to Ovid Therapeutics Inc’s price movement after its last earnings report?
Ovid Therapeutics Inc reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.223. Following the earnings report the stock price went up 6.954%.
Which hedge fund is a major shareholder of Ovid Therapeutics Inc?
Among the largest hedge funds holding Ovid Therapeutics Inc’s share is Driehaus Capital Management LLC. It holds Ovid Therapeutics Inc’s shares valued at N/A.
---
Ovid Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.70 (378.41% Upside)
$3.70 (378.41% Upside)
Blogger Sentiment
Neutral
OVID Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 14.7%
Last 30 Days ▲ 14.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.71%
12-Months-Change
Fundamentals
Return on Equity
-50.87%
Trailing 12-Months
Asset Growth
-8.20%
Trailing 12-Months
Company Description
Ovid Therapeutics Inc
Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.
---
OVID Stock 12 Month Forecast
Average Price Target
$3.70
▲(378.41% Upside)
Technical Analysis
Best Analysts Covering OVID
1 Year
1 Year Success Rate
8/14 ratings generated profit
1 Year Average Return
+44.74%
reiterated a buy rating yesterday
Copying Ritu Baral's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +44.74% per trade.
---